Gambro divests the Excorim immunoadsorption business

Gambro divests the Excorim immunoadsorption business Stockholm, Sweden - Gambro AB (Stockholm Stock Exchange: GAMBaST, GAMBbST), a leading international medical technology and healthcare com- pany, today announced that it has agreed to sell the Excorim immunoadsorp- tion business to Fresenius Hemocare effective January 24, 2000. Excorim is an operating unit of COBE BCT, a subsidiary of Gambro. In 1998 Excorim had sales of about SEK 30 M (USD 3.4 M). Excorim is specialized in immunoadsorption with the principal products immunoadsorption columns and equipment. The divestiture of Excorim is part of the strategic focusing of the COBE BCT business to blood bank technology and therapeutic specialties. For further information please contact: Ed Wood, President of COBE BCT, tel. +1-303-232-6800 Bengt Modéer, Senior Vice President, Corporate Communications, tel. +46-8- 613 65 00, +46-70-513 65 33 Anna Augustson, European Investor Relations Manager, tel. +46-8-613 65 35, +46-70-513 65 34 Gambro is a global medical technology and healthcare company with leading positions in renal care - services and products - and blood component technology (BCT). Gambro is one of the leading providers of kidney dialysis services in the world. Gambro treats about 43,200 patients in 581 clinics worldwide. Renal care products comprise dialyzers, dialysis machines, blood lines and dialysis concentrates. BCT includes products for the separation and handling of blood components. The group, with revenue of approximately SEK 18 billion (USD 2.2 billion), has approximately 17,000 employees in some 40 countries. ------------------------------------------------------------ Please visit http://www.bit.se for further information The following files are available for download: http://www.bit.se/bitonline/1999/12/14/19991214BIT00080/bit0001.doc http://www.bit.se/bitonline/1999/12/14/19991214BIT00080/bit0002.pdf